Compare ALKT & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALKT | ODTX |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2021 | 2025 |
| Metric | ALKT | ODTX |
|---|---|---|
| Price | $12.63 | $18.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $16.17 | ★ $34.67 |
| AVG Volume (30 Days) | ★ 2.1M | 272.0K |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $152,159,000.00 | N/A |
| Revenue This Year | $19.72 | N/A |
| Revenue Next Year | $14.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 35.68 | N/A |
| 52 Week Low | $12.10 | $15.10 |
| 52 Week High | $24.47 | $29.05 |
| Indicator | ALKT | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.18 | 42.69 |
| Support Level | $12.10 | $15.73 |
| Resistance Level | $14.52 | $19.60 |
| Average True Range (ATR) | 0.66 | 1.72 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 17.11 | 7.47 |
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.